Hansa Biopharma
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
HNSA | ST
Overview
Corporate Details
- ISIN(s):
- SE0002148817 (+1 more)
- LEI:
- 549300LLEO25ZJJ3NT91
- Country:
- Sweden
- Address:
- Box 785, 220 07 Lund
- Website:
- https://www.hansabiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative immunomodulating therapies for rare immunological diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology, which targets and inactivates immunoglobulin G (IgG) antibodies to inhibit harmful immune responses. This technology enables life-saving procedures, such as kidney transplantation for highly sensitized patients, and is being developed to treat a range of acute IgG-mediated autoimmune conditions. Key products include the enzyme imilfidase. The company's strategy involves drug discovery, development, commercialization, and partnerships to address significant unmet medical needs in transplantation and autoimmunity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-24 18:21 |
Earnings Release
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS t…
|
English | 260.2 KB | ||
| 2025-09-24 18:21 |
Earnings Release
Imlifidase når framgångsrikt primärt effektmått i den registreringsgrundande fa…
|
Swedish | 210.3 KB | ||
| 2025-09-02 17:30 |
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Hansa Biopharma AB (publ)
|
Swedish | 205.9 KB | ||
| 2025-09-02 17:30 |
Post-Annual General Meeting Information
Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)
|
English | 207.2 KB | ||
| 2025-09-02 14:48 |
Major Shareholding Notification
|
Swedish | 10.6 KB | ||
| 2025-08-07 07:00 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Hansa Biopharma AB (publ)
|
Swedish | 295.0 KB | ||
| 2025-08-07 07:00 |
Pre-Annual General Meeting Information
Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
|
English | 283.6 KB | ||
| 2025-08-01 21:15 |
Legal Proceedings Report
Hansa Biopharma announces supportive data from treatment with imlifidase prior …
|
English | 246.4 KB | ||
| 2025-08-01 21:15 |
Regulatory News Service
Hansa Biopharma tillkännager bekräftande resultat från behandling med imlifidas…
|
Swedish | 232.9 KB | ||
| 2025-07-17 07:00 |
Interim Report
|
Swedish | 1.6 MB | ||
| 2025-07-17 07:00 |
Interim Report
|
English | 1.4 MB | ||
| 2025-07-01 22:04 |
Major Shareholding Notification
|
Swedish | 9.8 KB | ||
| 2025-07-01 14:59 |
Major Shareholding Notification
|
Swedish | 9.5 KB | ||
| 2025-06-30 07:00 |
Share Issue/Capital Change
Hansa Biopharma: Ökning av antalet aktier och röster
|
Swedish | 208.0 KB | ||
| 2025-06-30 07:00 |
Share Issue/Capital Change
Hansa Biopharma: Increase in number of shares and votes
|
English | 204.6 KB |
Automate Your Workflow. Get a real-time feed of all Hansa Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Hansa Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-17 | Anne Säfström Lanner | Other | Sell | 10,487 | 443,285.49 SEK |
| 2024-06-17 | Sören Tulstrup | Other | Sell | 9,199 | 388,841.73 SEK |
| 2024-06-17 | Sören Tulstrup | Other | Buy | 35,200 | N/A |
| 2022-07-19 | Peter Nicklin | Other | Buy | 14,500 | 1,032,192.68 SEK |
| 2022-06-17 | Christian Kjellman | Other | Buy | 6,915 | 345,680.85 SEK |
| 2022-06-17 | Donato Spota | Other | Sell | 4,638 | 231,853.62 SEK |
| 2022-06-17 | Christian Kjellman | Other | Sell | 4,002 | 200,059.98 SEK |
| 2022-06-17 | Sören Tulstrup | Other | Sell | 3,925 | 196,210.75 SEK |
| 2022-06-17 | Sören Tulstrup | Other | Buy | 3,925 | 196,210.75 SEK |
| 2022-06-17 | Anne Säfström Lanner | Other | Sell | 2,685 | 134,223.15 SEK |
